Qulipta (atogepant) is a daily oral medication used to prevent migraine attacks in adults. It is FDA-approved for both episodic migraine (fewer than 15 headache days per month) and chronic migraine (15 or more headache days per month). Qulipta is not designed to stop a migraine once it starts; it’s taken every day to reduce how often migraines occur in the first place.
How Qulipta Prevents Migraines
Qulipta belongs to a class of drugs called CGRP receptor antagonists. During a migraine, a protein called CGRP floods the nervous system and sensitizes pain-signaling nerve fibers around the brain’s protective lining. This sensitization is what turns a mild signal into the throbbing, debilitating pain of a full migraine attack. Qulipta blocks the receptor that CGRP binds to, which prevents those nerve fibers from becoming sensitized in the first place.
What makes this mechanism interesting is that Qulipta doesn’t shut down all pain signaling. It primarily dampens the slower nerve pathways responsible for building and sustaining migraine pain, while leaving faster, general sensory pathways mostly intact. This selective action helps explain why the drug prevents migraines without numbing other sensations.
How Quickly It Works
Many people notice a difference within the first week. In clinical trials, people taking the 60 mg dose had a 53% reduction in weekly migraine days after just one week, compared to a 15% reduction in the placebo group. Some benefit appeared even sooner: 88% of people on the 60 mg dose were migraine-free the day after their first dose, versus 75% on placebo.
That said, the full benefit builds over time. Clinical trials measured outcomes across a 12-week treatment period, and reductions in migraine days continued to accumulate throughout that window. The early improvements are encouraging, but sticking with the medication gives it the best chance to work.
How Much It Reduces Migraine Days
For people with chronic migraine, the largest clinical trial (called PROGRESS) found that Qulipta 60 mg reduced monthly migraine days by about 2.4 more days than placebo over the first four weeks. That difference continued across the full 12-week treatment period. To put that in context, people with chronic migraine typically experience 8 or more migraine days per month at baseline, so a reduction of several additional days beyond what a placebo provides represents a meaningful change in quality of life.
For episodic migraine, multiple dose strengths (10 mg, 30 mg, and 60 mg) all showed reductions in monthly migraine days compared to placebo across 12 weeks of treatment. The availability of three dose options gives flexibility in balancing effectiveness with tolerability.
Available Doses
Qulipta comes in 10 mg, 30 mg, and 60 mg tablets, all taken once daily with or without food. For episodic migraine, any of the three strengths can be prescribed. For chronic migraine, the recommended dose is 60 mg once daily.
Your dose may need to be adjusted based on other medications you take. Certain drugs that affect how the liver processes Qulipta require a lower dose. For example, strong antifungal medications like ketoconazole or the antibiotic clarithromycin call for a reduction to 10 mg daily. The immunosuppressant cyclosporine also requires a lower dose. On the other hand, some medications (including the seizure drugs carbamazepine and phenytoin, and the herbal supplement St. John’s wort) speed up how the body clears Qulipta, so a higher dose of 30 mg or 60 mg is recommended when taking those. People with significant kidney impairment may also need dose adjustments.
Common Side Effects
The most frequently reported side effects are nausea, constipation, and fatigue or sleepiness. In the chronic migraine trial, among people taking the 60 mg dose, 10% reported upper respiratory tract infections, 7% had constipation, 6% experienced nausea, and 5% reported urinary tract infections. These rates were modestly higher than placebo but low enough that most people stayed on the medication. About 5.7% of people on the 60 mg dose discontinued due to side effects, and at lower doses the discontinuation rate was even smaller (3.1% to 4.1%).
Weight loss is a less commonly discussed effect. In clinical trials, 5.3% of people on the 60 mg dose lost at least 7% of their body weight at some point during treatment, compared to 2.5% on placebo. In one longer-duration study, that figure rose to 24.1% for the 60 mg dose. This isn’t listed as a therapeutic benefit, but it’s worth being aware of, particularly if you notice unexpected changes on the scale.
How Qulipta Differs From Acute Migraine Treatments
Qulipta is strictly a preventive medication. It won’t relieve a migraine that’s already happening. Drugs designed to treat active migraine attacks, like triptans or the related medication Ubrelvy (ubrogepant), work differently and are taken only when symptoms strike. Many people use Qulipta daily for prevention alongside a separate acute treatment for breakthrough attacks.
Another related medication, Nurtec ODT (rimegepant), also targets the CGRP pathway but is approved for both prevention and acute treatment. Qulipta’s approval is limited to prevention, which means it was specifically developed and tested for that single purpose. If you’re comparing options, the key distinction is whether you need a daily preventive, an as-needed treatment, or both.